140 related articles for article (PubMed ID: 36696982)
1. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study.
Fan W; Ding J; Zhong W
Tohoku J Exp Med; 2023 May; 260(1):13-20. PubMed ID: 36696982
[TBL] [Abstract][Full Text] [Related]
2. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Yang H; Geng A; Wang Z; Wu C
J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
Li C; Yu F; Xu W
J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
8. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
9. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
Ma N; Qiao H; Tao H; Gan X; Shan Z; Chen X; Zhou X
Clin Res Hepatol Gastroenterol; 2022; 46(7):101962. PubMed ID: 35636681
[TBL] [Abstract][Full Text] [Related]
10. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.
Li DD; Tao ZH; Wang BY; Wang LP; Cao J; Hu XC; Zhang J
NPJ Breast Cancer; 2022 Sep; 8(1):110. PubMed ID: 36127351
[TBL] [Abstract][Full Text] [Related]
11. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.
Li YH; Zhou Y; Wang YW; Tong L; Jiang RX; Xiao L; Zhang GJ; Xing SS; Qian F; Feng JQ; Zhao YL; Wang JG; Wang XH
Medicine (Baltimore); 2018 Sep; 97(36):e12222. PubMed ID: 30200142
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study.
Liu Z; Zheng Z; Dong L; Guo X; Jia X; Wang J; Meng L; Cui X; Jiang X
Sci Rep; 2022 Oct; 12(1):18327. PubMed ID: 36316341
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.
Tan A; Nong L; Wang H; Jia Y; Zhong W; Qin F; Wang H; Tang J; Liu Y; Lu Y
Cancer Biol Ther; 2023 Dec; 24(1):2265055. PubMed ID: 37831547
[TBL] [Abstract][Full Text] [Related]
16. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
Xia X; Jiang W; Qi W; Hong B; Zhao W
Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Du F; Yuan P; Luo Y; Wang J; Ma F; Cai R; Fan Y; Li Q; Zhang P; Xu B
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):788-92. PubMed ID: 26813602
[TBL] [Abstract][Full Text] [Related]
20. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
